Atlas Trials

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT06395870 · RECRUITING

Trial details

NCT number
NCT06395870
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Start date
2024-05-09
Primary completion
2026-06-30
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.